Rice Lyndi M, Donigan Melissa, Yang Muhua, Liu Weidong, Pandya Devanshi, Joseph Biny K, Sodi Valerie, Gearhart Tricia L, Yip Jenny, Bouchard Michael, Nickels Joseph T
From the Oncoveda Cancer Institute and.
the Institute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, New Jersey 08691 and.
J Biol Chem. 2014 Jun 13;289(24):17268-79. doi: 10.1074/jbc.M114.570390. Epub 2014 Apr 26.
LDL-cholesterol (LDL-C) uptake by Ldlr is regulated at the transcriptional level by the cleavage-dependent activation of membrane-associated sterol response element-binding protein (SREBP-2). Activated SREBP-2 translocates to the nucleus, where it binds to an LDLR promoter sterol response element (SRE), increasing LDLR gene expression and LDL-C uptake. SREBP-2 cleavage and translocation steps are well established. Several SREBP-2 phosphorylation sites have been mapped and functionally characterized. The phosphatases dephosphorylating these sites remain elusive. The phosphatase(s) regulating SREBP-2 represents a novel pharmacological target for treating hypercholesterolemia. Here we show that protein phosphatase 2A (PP2A) promotes SREBP-2 LDLR promoter binding in response to cholesterol depletion. No binding to an LDLR SRE was observed in the presence of the HMG-CoA reductase inhibitor, lovastatin, when PP2A activity was inhibited by okadaic acid or depleted by siRNA methods. SREBP-2 cleavage and nuclear translocation were not affected by loss of PP2A. PP2A activity was required for SREBP-2 DNA binding. In response to cholesterol depletion, PP2A directly interacted with SREBP-2 and altered its phosphorylation state, causing an increase in SREBP-2 binding to an LDLR SRE site. Increased binding resulted in induced LDLR gene expression and increased LDL uptake. We conclude that PP2A activity regulates cholesterol homeostasis and LDL-C uptake.
低密度脂蛋白受体(Ldlr)对低密度脂蛋白胆固醇(LDL-C)的摄取在转录水平上受膜相关固醇反应元件结合蛋白(SREBP-2)的切割依赖性激活调控。活化的SREBP-2易位至细胞核,在那里它与低密度脂蛋白受体启动子固醇反应元件(SRE)结合,增加低密度脂蛋白受体基因表达和LDL-C摄取。SREBP-2的切割和易位步骤已得到充分证实。多个SREBP-2磷酸化位点已被定位并进行了功能表征。使这些位点去磷酸化的磷酸酶仍不明确。调节SREBP-2的磷酸酶是治疗高胆固醇血症的新型药理学靶点。在此我们表明,蛋白磷酸酶2A(PP2A)在胆固醇耗竭时促进SREBP-2与低密度脂蛋白受体启动子的结合。当PP2A活性被冈田酸抑制或通过小干扰RNA方法耗尽时,在存在HMG-CoA还原酶抑制剂洛伐他汀的情况下,未观察到与低密度脂蛋白受体SRE的结合。PP2A的缺失不影响SREBP-2的切割和核易位。SREBP-2与DNA的结合需要PP2A活性。在胆固醇耗竭时,PP2A直接与SREBP-2相互作用并改变其磷酸化状态,导致SREBP-2与低密度脂蛋白受体SRE位点的结合增加。结合增加导致低密度脂蛋白受体基因表达诱导和低密度脂蛋白摄取增加。我们得出结论,PP2A活性调节胆固醇稳态和LDL-C摄取。